Antibody–drug conjugates (ADCs) have received significant attention due to their impact on the cancer drug development field. The efficacy of these compounds is attributed to the targeted tumor delivery of cytotoxic payloads. The targeting precision of antibodies enables direct payload delivery to cancer cells where the conjugate is internalised and causes cell death.
One problem with current ADC technology is the difficulty creating conjugates with a uniform drug to antibody ratio and consistent payload placement on the antibody. More challenges are discussed in a recent publication produced by FiercePharmaBiotech sposored by Catalent titled, "Targeted Cancer Treatments: A Progress Report."
Catalent has entered into an exclusive license and co-marketing agreement with Redwood Bioscience to offer its customers Redwood’s advanced site-specific conjugation SMARTag™ technology to develop optimized Antibody Drug Conjugates and solve the major challenges in the production of ADCs.
SMARTag technology enables a simple and efficient chemoenzymatic approach for generating uniform antibody drug conjugates:
SMARTag™ ADC technology enables biologic innovators to develop moreefficacious antibody drug conjugates faster. Developed by Redwood Bioscience, this new platform leverages Catalent’s biologic drug development expertise, advanced GPEx® expression system, clinical biomanufacturing and integrated services, offering a number of advantages to ADC developers:
Currently the pre-clinical ADC production involves both Catalent Madison and Redwood facilities. Biologics incorporating the SMARTag™ Technology are produced in Catalent's Madison, IL facility. Pre-clinical conjugation/toxin loading is performed at Redwood Biosciences in Emeryville, California.